|
|
|
November 2005
Axxam Opens New Facility at Polaris Science and Technology Park (Cagliari)
Axxam announced the opening of its new research facility at Polaris, the Scientific and Technological Park of Sardinia (Italy), a new centre of excellence for biotechnology. The new Axxam facility is located in the life science technologies centre in Pula (Cagliari) where pharmacology and genomics research is conducted by specialised laboratories.
POLARIS is a multipolar and multisectorial park financed by a joint of effort of the European Commission and the Sardinian Regional Government that promotes research and technology transfer.
November 2005
Axxam Appoints Suzanne Beveridge as Chief Corporate Communications
Suzanne Beveridge has joined Axxam as Chief Corporate Communications, a newly-created position that will direct corporate communications strategy and manage public relations and marketing communications for the rapidly-growing biotechnology company. She has more than 20 years of career experience in life sciences. She builds on her strong science base to facilitate effective communications for the biotechnology industry.
Prior to Axxam, Suzanne Beveridge led Corporate Communications for biotechnology company Scios Inc. in California, USA. She previously held positions in investor relations and international business development at the headquarters of Amgen Inc., a leading human therapeutics company in the biotechnology industry, in Thousand Oaks, California following several years in sales and marketing roles at the Australian subsidiary of Amgen.
Suzanne Beveridge graduated with a degree in Medical Laboratory Science from the Queensland University of Technology in Australia and she holds a Master of Business in International Marketing from the University of Technology Sydney, Australia.
September 2005
Axxam Researchers Present at the 11th SBS Conference in Geneva, Switzerland
At the 11th Society of Biomedical Screening (SBS) Conference, Geneva (Switzerland), Axxam scientists made podium presentations on the following topics:
Axxam representatives also exhibited and discussed competencies and services of the company in the trade display area at the conference.
September 2005
Axxam Appoints Luigi Gavazzeni as Chief Financial Officer
Luigi Gavazzeni has been appointed Chief Financial Officer of Axxam. This newly-created position will be responsible for the financial management of the growing biotechnology company. His experience in the Italian biotechnology industry allows him to make considerable contribution to the strategic direction of the company.
Prior to Axxam, Luigi Gavazzeni held Finance Director positions at, most recently, Bioxell SpA and before that at Novuspharma SpA. He previously successfully managed several projects for a number of companies in the biopharmaceutical industry.
Dr. Gavazzeni received his Degree in Engineering from the Polytechnic in Milan and subsequently obtained a certificate for "EU advanced workshop: economics and management in biotechnology companies."
August 2005
Axxam Awarded FIT Grant for Novel Target Identification
Axxam is pleased to announce the award of a grant from the Italian Ministero delle Attività; Produttive (MAP). The grant of €2.93 million will support a three year project in the field of novel target identification for pharmaceutical screening and recognizes the contribution of Axxam to Technological Innovation in the Regione Lombardia (Fondo speciale rotativo per l'Innovazione Technologica, FIT).
The funding will allow Axxam scientists to apply various technology platforms with the goal to identify novel and durable targets in selected therapeutic areas, such as pain, osteoporosis and chronic obstructive pulmonary disease (COPD)/asthma.
The grant consists of a non-refundable portion (40 per cent) and financing for the remaining 60 percent repayable over a 13-year period with favourable terms.
July 2005
Axxam Appoints Dr. Tod Flak as Head of Screening Technologies
Dr. Tod Flak (PhD) has been appointed Head of the Screening Technologies group for Axxam. Since 2002, Dr. Flak's role at Axxam was as a senior researcher in the Bioinformatics group
Prior to Axxam, Dr. Flak worked with several biotechnology companies in San Francisco, California, USA. He has broad technology experience including the development of robotic automation for biological assays and chemical synthesis, the development of software to support laboratory research, and the development and administration of databases for laboratory information management and chemical registration.
Dr. Flak received his Bachelor of Science in Electrical Engineering at Case Western Reserve University in Cleveland, Ohio, USA; and a Ph.D. in Molecular Microbiology from Washington University in St. Louis, Missouri, USA. His postdoctoral training was at the genome sequencing facility at Lawrence Berkeley National Laboratory in California, USA.
June 2005
Axxam Invests in Screening Technologies
Axxam installed a new technology platform for performing robotic high throughput screening (HTS) and ultra high-throughput screening (uHTS) of chemical libraries. Axxam implemented the most advanced instrumentation (CyBiTM-Cellight (CyBio AG) and FLIPRtetraTM (Molecular Devices Corporation Inc.) in a highly integrated and centralized structure, capable of performing screening campaigns which can generate over a million test points per day.
The new instrumentation operates with 384-well and 1536-well microtitre plates (MTPs) and provides a technologically advanced automated screening station integrating downstream existing platforms of bioinformatics, target biology and cellular and biochemical screening assay development.
March 2005
Axxam Receives European Patent for Innovative Technology Photina®
Axxam is pleased to announce the award of European Patent number EP1413584,
entitled "Photoprotein with improved bioluminescence", describing the company's proprietary photoprotein known as Photina®. The invention provides a chimeric photoprotein with improved luminescent activity and its use as a calcium indicator in reporter gene systems and in cell-based assays for the detection and measurement of intracellular calcium. This novel calcium-detecting photoprotein yields superior signal levels and is applicable to a large number of different screening platforms for the pharmaceutical industry and for the study of any biological process involving calcium release.
February 2005
Axxam Collaborates with CyBio AG
Axxam and CyBio have signed a contract to cooperate in the development and marketing of new technologies for drug discovery using automated luminescence screening systems.
Open PDF document (17.3K)
January 2005
Axxam Awarded € 1.1 million grant
Axxam Awarded Substantial Funding by the Regione Lombardia (Metadistretti) with € 1.1 million grant to support one of the company's innovative projects in the field of Cell-based Screening Assays
|
|
|
|
|
|
|
